适体
人血清白蛋白
白蛋白
循环肿瘤细胞
化学
癌症研究
癌细胞
癌症
生物物理学
分子生物学
医学
生物
生物化学
内科学
转移
作者
Jie Wang,Huo Xu,Shuhui Li,Min Lin,Yusheng Lu,Kuancan Liu,Vladimir L. Katanaev,Evgeny V. Denisov,Lee Jia
出处
期刊:Nano Today
[Elsevier]
日期:2023-12-01
卷期号:53: 102002-102002
标识
DOI:10.1016/j.nantod.2023.102002
摘要
Circulating tumor cells (CTC) are the root cause of life-threatening cancer metastases. The rare CTC cannot be specifically killed by anti-cancer agents without producing any side effects, nor be targeted-and-eradicated by antibody or aptamer complexes because of the complexes’ limited circulating half-life in the blood owing to metabolism and immune clearance. Here, we build the biosafe and biostable aptamer-albumin nanobots that can cruise in the blood much long together with the CTC, resulting in the increased capture efficiency and specificity of the nanobots targeting CTC. The intelligent-recognizing unit of the novel nanobots is composed of three EpCAM-targeting aptamers (AP) that can specifically target breast CTC, and their sticky ends are completely closed to form the biostable circular trivalent aptamers (CTA). The binding energy, specificity and stability of the circular three arms CTA are significantly superior to their linear AP. After conjugating CTA to human serum albumin (CTA-HSA) by amination reaction, the blood circulation time of CTA-HSA in mice was significantly prolonged by 3 folds, resulting in the enhanced collision probability and increased capture efficiency of CTA-HSA to CTC. CTA-HSA can escape the immune clearance and inhibit adhesion/invasion and cell cycle of CTC, resulting in CTC apoptosis. This proof-of-concept study provides a promising nanobiomaterial for CTC-induced cancer metastases.
科研通智能强力驱动
Strongly Powered by AbleSci AI